Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 120


The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers.

Leong CO, Vidnovic N, DeYoung MP, Sgroi D, Ellisen LW.

J Clin Invest. 2007 May;117(5):1370-80. Epub 2007 Apr 19.


BRCA1-associated epigenetic regulation of p73 mediates an effector pathway for chemosensitivity in ovarian carcinoma.

Ibrahim N, He L, Leong CO, Xing D, Karlan BY, Swisher EM, Rueda BR, Orsulic S, Ellisen LW.

Cancer Res. 2010 Sep 15;70(18):7155-65. doi: 10.1158/0008-5472.CAN-10-0668. Epub 2010 Aug 31.


One, two, three--p53, p63, p73 and chemosensitivity.

Müller M, Schleithoff ES, Stremmel W, Melino G, Krammer PH, Schilling T.

Drug Resist Updat. 2006 Dec;9(6):288-306. Epub 2007 Feb 6. Review.


Tumor-specific p73 up-regulation mediates p63 dependence in squamous cell carcinoma.

DeYoung MP, Johannessen CM, Leong CO, Faquin W, Rocco JW, Ellisen LW.

Cancer Res. 2006 Oct 1;66(19):9362-8.


TAp73-mediated the activation of c-Jun N-terminal kinase enhances cellular chemosensitivity to cisplatin in ovarian cancer cells.

Zhang P, Liu SS, Ngan HY.

PLoS One. 2012;7(8):e42985. doi: 10.1371/journal.pone.0042985. Epub 2012 Aug 10.


p63 mediates survival in squamous cell carcinoma by suppression of p73-dependent apoptosis.

Rocco JW, Leong CO, Kuperwasser N, DeYoung MP, Ellisen LW.

Cancer Cell. 2006 Jan;9(1):45-56.


TNF-α promotes c-REL/ΔNp63α interaction and TAp73 dissociation from key genes that mediate growth arrest and apoptosis in head and neck cancer.

Lu H, Yang X, Duggal P, Allen CT, Yan B, Cohen J, Nottingham L, Romano RA, Sinha S, King KE, Weinberg WC, Chen Z, Van Waes C.

Cancer Res. 2011 Nov 1;71(21):6867-77. doi: 10.1158/0008-5472.CAN-11-2460. Epub 2011 Sep 20.


A microRNA-dependent program controls p53-independent survival and chemosensitivity in human and murine squamous cell carcinoma.

Ory B, Ramsey MR, Wilson C, Vadysirisack DD, Forster N, Rocco JW, Rothenberg SM, Ellisen LW.

J Clin Invest. 2011 Feb;121(2):809-20. doi: 10.1172/JCI43897. Erratum in: J Clin Invest. 2014 Mar 3;124(3):1418.


TNF-α modulates genome-wide redistribution of ΔNp63α/TAp73 and NF-κB cREL interactive binding on TP53 and AP-1 motifs to promote an oncogenic gene program in squamous cancer.

Si H, Lu H, Yang X, Mattox A, Jang M, Bian Y, Sano E, Viadiu H, Yan B, Yau C, Ng S, Lee SK, Romano RA, Davis S, Walker RL, Xiao W, Sun H, Wei L, Sinha S, Benz CC, Stuart JM, Meltzer PS, Van Waes C, Chen Z.

Oncogene. 2016 Nov 3;35(44):5781-5794. doi: 10.1038/onc.2016.112. Epub 2016 May 2.


Transcription factors Sp1 and p73 control the expression of the proapoptotic protein NOXA in the response of testicular embryonal carcinoma cells to cisplatin.

Grande L, Bretones G, Rosa-Garrido M, Garrido-Martin EM, Hernandez T, Fraile S, Botella L, de Alava E, Vidal A, Garcia del Muro X, Villanueva A, Delgado MD, Fernandez-Luna JL.

J Biol Chem. 2012 Aug 3;287(32):26495-505. doi: 10.1074/jbc.M112.376319. Epub 2012 Jun 20.


The integrin alpha(v)beta(3-5) ligand MFG-E8 is a p63/p73 target gene in triple-negative breast cancers but exhibits suppressive functions in ER(+) and erbB2(+) breast cancers.

Yang C, Hayashida T, Forster N, Li C, Shen D, Maheswaran S, Chen L, Anderson KS, Ellisen LW, Sgroi D, Schmidt EV.

Cancer Res. 2011 Feb 1;71(3):937-45. doi: 10.1158/0008-5472.CAN-10-1471. Epub 2010 Dec 2.


Rescue of platinum-damaged oocytes from programmed cell death through inactivation of the p53 family signaling network.

Kim SY, Cordeiro MH, Serna VA, Ebbert K, Butler LM, Sinha S, Mills AA, Woodruff TK, Kurita T.

Cell Death Differ. 2013 Aug;20(8):987-97. doi: 10.1038/cdd.2013.31. Epub 2013 Apr 19.


Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo.

Concin N, Hofstetter G, Berger A, Gehmacher A, Reimer D, Watrowski R, Tong D, Schuster E, Hefler L, Heim K, Mueller-Holzner E, Marth C, Moll UM, Zeimet AG, Zeillinger R.

Clin Cancer Res. 2005 Dec 1;11(23):8372-83.


p73, a sophisticated p53 family member in the cancer world.

Ozaki T, Nakagawara A.

Cancer Sci. 2005 Nov;96(11):729-37. Review.


p63 and p73 in human cancer: defining the network.

Deyoung MP, Ellisen LW.

Oncogene. 2007 Aug 9;26(36):5169-83. Epub 2007 Mar 5. Review.


PLK2 phosphorylates and inhibits enriched TAp73 in human osteosarcoma cells.

Hu ZB, Liao XH, Xu ZY, Yang X, Dong C, Jin AM, Lu H.

Cancer Med. 2016 Jan;5(1):74-87. doi: 10.1002/cam4.558. Epub 2015 Dec 2.


p63 and p73: roles in development and tumor formation.

Moll UM, Slade N.

Mol Cancer Res. 2004 Jul;2(7):371-86. Review.


The p53-family members p63 and p73 inhibit insulin-like growth factor-I receptor gene expression in colon cancer cells.

Nahor I, Abramovitch S, Engeland K, Werner H.

Growth Horm IGF Res. 2005 Dec;15(6):388-96. Epub 2005 Sep 21.


Netrin-1 induces apoptosis in human cervical tumor cells via the TAp73alpha tumor suppressor.

Roperch JP, El Ouadrani K, Hendrix A, Emami S, De Wever O, Melino G, Gespach C.

Cancer Res. 2008 Oct 15;68(20):8231-9. doi: 10.1158/0008-5472.CAN-08-1483.

Supplemental Content

Support Center